Literature DB >> 18780149

Survival analysis: up from Kaplan-Meier-Greenwood.

Olli S Miettinen1.   

Abstract

In the type of survival analysis that now is routine, only the points of follow-up at which deaths from the cause at issue occurred make contributions to the Greenwood standard error (SE) of the survival rate's Kaplan-Meier (KM) point estimate. An equivalent of this 'KMG' analysis draws from defined subintervals of the survival period being addressed. The data on each subinterval consist of the number of deaths from the cause at issue and the amount of population-time of follow-up, d(j) and T(j), together with the duration of the interval, t(j). The KM point estimate is replicated by exp[-Sigma(j)(d(j)/T(j))t(j)], and the KMG interval estimate is replicated by treating the {d(j)} as a set of point estimates of Poisson parameters {lambda(j)}, thus taking the SE of Sigma(j)(d(j)/T(j))t(j) to be [Sigma(j)(d(j)/T(j))2](1/2). In both the KMG analysis and this equivalent of it, the SE used to derive the survival rate's lower confidence limit needs to be augmented by a factor that accounts for the loss of information due to censorings subsequent to the last 'failure' in the survival period at issue. But, SE-based interval estimation of survival rate actually needs to be replaced by a first-principles counterpart of it. A suitable point of departure in this is first-principles asymptotic interval estimation of the Poisson parameter lambda=Sigma(j)lambda(j), if not the exact counterpart of this. A confidence limit for the survival rate can then be based on suitable augmentation or contraction of the {d(j)} set to {d(j)*} consistent with a given limit for lambda, the corresponding survival-rate limit being exp[-Sigma(j)(d(j)*/T(j))t(j)]. Suitable augmentation is constituted by an identical addition to each d(j)(1/2) suitable contraction by an identical subtraction from each d(j)(1/2) >or= 1.

Entities:  

Mesh:

Year:  2008        PMID: 18780149     DOI: 10.1007/s10654-008-9278-7

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  4 in total

1.  A simple hybrid variance estimator for the Kaplan-Meier survival function.

Authors:  Craig B Borkowf
Journal:  Stat Med       Date:  2005-03-30       Impact factor: 2.373

2.  Survival of patients with stage I lung cancer detected on CT screening.

Authors:  Claudia I Henschke; David F Yankelevitz; Daniel M Libby; Mark W Pasmantier; James P Smith; Olli S Miettinen
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

3.  Cigarette-smoking and nonfatal myocardial infarction: rate ratio in relation to age, sex and predisposing conditions.

Authors:  O S Miettinen; R K Neff; H Jick
Journal:  Am J Epidemiol       Date:  1976-01       Impact factor: 4.897

4.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  4 in total
  7 in total

1.  Up from 'false positives' in genetic-and other-epidemiology.

Authors:  Olli S Miettinen
Journal:  Eur J Epidemiol       Date:  2008-10-22       Impact factor: 8.082

2.  Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial.

Authors:  Caryn M Upton; Rob C van Wijk; Laurynas Mockeliunas; Ulrika S H Simonsson; Kirsten McHarry; Gerben van den Hoogen; Chantal Muller; Arné von Delft; Helene-Mari van der Westhuizen; Reinout van Crevel; Gerhard Walzl; Pedro M Baptista; Jonathan Peter; Andreas H Diacon
Journal:  EClinicalMedicine       Date:  2022-05-12

3.  The Generation R Study: design and cohort update 2010.

Authors:  Vincent W V Jaddoe; Cock M van Duijn; Albert J van der Heijden; Johan P Mackenbach; Henriëtte A Moll; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2010-10-22       Impact factor: 8.082

4.  Using a Counting Process Method to Impute Censored Follow-Up Time Data.

Authors:  Jimmy T Efird; Charulata Jindal
Journal:  Int J Environ Res Public Health       Date:  2018-04-05       Impact factor: 3.390

5.  SFTA1P, LINC00968, GATA6-AS1, TBX5-AS1, and FEZF1-AS1 are crucial long non-coding RNAs associated with the prognosis of lung squamous cell carcinoma.

Authors:  Youwen Xiong; Xinyi Zhang; Zhuohui Lin; Aizhen Xiong; Shanshan Xie; Jia Liang; Weifang Zhang
Journal:  Oncol Lett       Date:  2019-08-14       Impact factor: 2.967

6.  Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden.

Authors:  Juan Vaz; Ulf Strömberg; Berne Eriksson; David Buchebner; Patrik Midlöv
Journal:  BMC Public Health       Date:  2020-11-30       Impact factor: 3.295

7.  Factors Associated with Discharge to a Skilled Nursing Facility after Transcatheter Aortic Valve Replacement Surgery.

Authors:  Carolyn E Horne; Tamara S Goda; L Wiley Nifong; Alan P Kypson; Wesley T O'Neal; Linda C Kindell; Charulata Jindal; Jimmy T Efird
Journal:  Int J Environ Res Public Health       Date:  2018-12-28       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.